Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure

Novartis Foundation Symposium

Volumn 274, Issue , 2006, Pages 73-83

  Taylor, Matthew R ^a   Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; GENOME; HEART DISEASE; HEART MUSCLE; HUMAN; METABOLISM; PATHOLOGY; PHENOTYPE; REVIEW;

CARDIOMYOPATHIES; GENE EXPRESSION REGULATION; GENOME, HUMAN; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 39049176416     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (34)

1. Abraham WT, Gilbert EM, Lowes BD et al 2002 Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med 8:750-760
2. Andersson B, Blange I, Sylven C 1999 Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail 1:363-369
3. Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC 2002 Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 160:2035-2043
4. Bleumink GS, Schut AF, Sturkenboom MC, Deckers JW, van Duijn CM, Stricker BH 2004 Genetic polymorphisms and heart failure. Genet Med 6:465-474
5. Bristow MR, Krause-Steinrauf H, Nuzzo R 2004a Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial (BEST). Circulation 110:1437-1442
6. Bristow MR, Mestroni L, Bohlmeyer TJ, Gilbert EM 2004b Dilated cardiomyopathies: In: Fuster V, Alexander RW, O'Rourke RA (eds) Hurst's The Heart, 11th edn. McGraw-Hill, p 1889-1907
7. 2C-Adrenergic receptor 322-325 DEL polymorphism enhanced the sympatholytic effect of bucindolol, and adversely affected clinical outcomes in the BEST Trial. Circulation (AHA 2005), 112:2-351
8. Burkett EL, Hershberger RE 2005 Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 45:969-981
9. Carniel E, Taylor MR, Sinagra G 2005 Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 112:54-59
10. Charron P, Tesson F, Poirier O 1999 Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur Heart J 20:1587-1591
11. Cohn JN, Pfeffer MA, Rouleau J et al 2003 Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5:659-667
12. Couzin J 2005 American association for the advancement of science meeting. DNA tells story of heart drug failure. Science 307:1191
13. Friddle CJ, Koga T, Rubin EM, Bristow J 2000 Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci USA 97:6745-6750
14. Human genome sequencing consortium 2004 Finishing the euchromatic sequence of the human genome. Nature 431:931-945
15. Hwang JJ, Allen PD, Tseng GC et al 2002 Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics 10:31-44
16. Jongeneel CV, Iseli C, Stevenson BJ et al 2003 Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci 100:4702-4705
17. Kitaura-Inenaga K, Hara M, Higuchi K et al 2003 Gene expression of cardiac mast cell chymase and tryptase in a murine model of heart failure caused by viral myocarditis. Circ J 67: 881-884
18. Lowes BD, Minobe WA, Abraham WT et al 1997 Changes in gene expression in the intact human heart: down-regulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100:2315-2324
19. Lowes BD, Minobe WA, Good M et al 2002a Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: functional categories of genes exhibiting altered expression with improvement in phenotype. Circulation 106:II-384
20. Lowes BD, Gilbert EM, Abraham WT et al 2002b Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. New Engl J Med 346:1357-1365
21. McNamara DM, Holubkov R, Janosko K et al 2001 Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103:1644-1648
22. Mialet Perez J, Rathz DA, Petrashevskaya NN et al 2003 Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9:1300-1305
23. Morita H, Seidman J, Seidman CE 2005 Genetic causes of human heart failure. J Clin Invest 115:518-526
24. Nabel EG 2003 Cardiovascular disease. N Engl J Med 349:60-72
25. Pasotti M, Repetto A, Tavazzi L, Arbustini E 2004 Genetic predisposition to heart failure. Med Clin North Am 88:1173-1192
26. Raynolds MV, Bristow MR, Bush EW et al 1993 Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 342:1073-1075
27. Schut AF, Bleumink GS, Stricker BH et al 2004 Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur Heart J 25:2143-2148
28. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB 2002 Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135-1142
29. Stanton LW, Garrard LJ, Damm D et al 2000 Altered patterns of gene expression in response to myocardial infarction. Circ Res 86:939-945
30. Taylor MR, Bristow MR 2004 The emerging pharmacogenomics of the beta-adrenergic receptors. Congest Heart Fail 10:281-288
31. Taylor MR, Carniel E, Mestroni L 2003 Familial dilated cardiomyopathy. In: Orphanet Databases. http://www.orpha.net
32. Taylor MR, Carniel E, Mestroni L 2004 Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing. Expert Rev Mol Diagn 4:99-113
33. Waldenstrom A, Schwartz K, Swynghedauw B 1989 Cardiac hypertrophy: from fetal to fatal? Clin Physiol 9:315-320
34. Yussman MG, Toyokawa T, Odley A et al 2002 Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 8:725-730